Wontiaxone Injection 1 Gram (Ceftriaxone Sodium Hydrate)

Adult administration

Adults and children over 12 years: Administer 1–2g (potency) of ceftriaxone once daily by intravenous or intramuscular injection. For infections caused by more severe pathogens or pathogens with moderate susceptibility, the dose can be increased up to 4g (potency) once daily. For gonorrhea treatment, a single intramuscular dose of 250mg (potency) is recommended. For prevention of preoperative and postoperative infections, a single dose of 1–2g (potency) should be given 30–90 minutes before surgery.

Child administration

Neonates (up to 14 days of life): Administer 20–50mg (potency) per Kg of body weight once daily, not exceeding 50mg (potency). Infants and children (from 15 days to 12 years): Administer 2

This medication should not be mixed or administered concurrently with calcium-containing solutions. In particular, if administered to neonates, precipitation may occur leading to serious side effects, so it must not be given. Patients who are allergic to this medication or have had hypersensitivity reactions to cephalosporins or penicillin antibiotics should avoid its use. It should not be administered to premature infants, neonates with jaundice, or those with impaired bilirubin binding. During administration, periodic checks for allergic reactions, renal function, liver function, etc., are necessary, and if any abnormal symptoms appear, administration should be stopped immediately. Serious side effects may occur, including hypersensitivity reactions, shock, severe skin reactions, blood abnormalities, and neurological side effects, necessitating close monitoring of the patient's condition before and after administration. The safety of this medication during pregnancy has not been established, so it should only be administered judiciously when necessary, with caution also advised during breastfeeding. Elderly or patients with impaired renal function should take care with dose adjustments and intervals of administration. This medication may interact with other antibiotics, diuretics, or calcium preparations, so any concomitant medications must be disclosed. After administration, it may affect blood sugar tests or urine sugar tests, so this should be noted during testing. The prepared solution should be used as soon as possible, and care should be taken in storage.

Serious side effects

Hives, severe swelling (edema), chest tightness, difficulty breathing, cold sweat, paleness, severe rash with high fever, blisters, skin peeling, pain in mouth/ocular mucous membranes, difficulty breathing or shortness of breath, asthma attacks, respiratory issues accompanied by cough and fever, yellowing of skin or eyes (jaundice), extreme lethargy, sudden and severe headache, thunderclap headache, seizures, confusion, visual disturbances, paralysis, urination

Mild side effects

• Eosinophilia
• leukopenia
• thrombocytopenia
• diarrhea
• rash
• increased liver enzymes
• headache
• dizziness
• bronchospasm
• loose stools

This medication should be stored in a sealed container to prevent exposure to air, and it is safest to store at a temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness.

Appearance

A vial containing a white to pale yellow powder

Package unit

For domestic use: 1g (potency) / vial x 10, For export: 1g (potency) / vial x 10